Αρχική World News Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated... World News Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC Από Ogkologos - 14 Νοεμβρίου, 2025 360 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... 16 Φεβρουαρίου, 2022 Study Shows Thymic Health is Linked to Cancer Patients’ Response to... 16 Οκτωβρίου, 2025 Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and... 15 Ιουλίου, 2021 ΣΤΑΤΙΣΤΙΚΑ 18 Ιανουαρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic... Honoring Other’s Wishes ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer...